NSC 680410

10/01/2003 - "NSC 680410 potentiated the activity of IDA in both leukemia cell lines by 17.8- and 221.4-fold in the WT and drug-resistant line, respectively. "
12/08/2006 - "Adaphostin (NSC680410), a small molecule congener of tyrphostin AG957, has been demonstrated previously to have significant anti-proliferative effects in several leukemia models. "
03/15/2006 - "In view of this unique mode of action, we examined the effects of adaphostin on numerous imatinib-resistant leukemia models, including imatinib-resistant CML and Ph+ ALL cell lines, cells harboring point mutations in BCR/ABL, and specimens from imatinib-resistant CML patients, using assays for intracellular ROS, apoptosis, and clonogenicity. "
12/15/2003 - "Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells."
12/01/2002 - "In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines."

01/01/2021 - "4a and 4b, exhibited similar cytotoxic activity with adaphostin against the tested cancer cell lines. "
12/08/2006 - "However, this effect of adaphostin in adherent cells/solid tumor models has not been examined. "
09/01/2005 - "Thus, adaphostin remains an interesting agent with the ability to kill tumor cells directly and modulate angiogenesis."
07/09/2010 - "Inhibition of Nrf2 translocation by wortmannin inhibited this cytoprotective response, and enhanced the toxicity of adaphostin, suggesting that inhibitors of the PI3K pathway, such as wortmannin, might augment the antiproliferative effects of adaphostin in solid tumors that depend on the Nrf2/ARE pathway for protection against oxidative stress."
01/01/2009 - "This differential sensitivity between cancer cells and normal cells may have important clinical applications, as it has been observed with other pro-oxidants like Arsenic trioxide, isothiocyanates, Adaphostin."

05/01/2009 - "Given the large number of targeted chemotherapies, in this review, we focus on selected agents that have shown promise in hematologic malignancies: proteasome inhibitors, histone deacetylase inhibitors, Bcl-2-targeted agents, and a kinase inhibitor called adaphostin. "

09/01/2006 - "Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells."
12/15/2003 - "Initial studies demonstrated that adaphostin induced apoptosis in a variety of Bcr/abl- cells, including acute myelogenous leukemia (AML) blasts and cell lines as well as chronic lymphocytic leukemia (CLL) samples. "
09/01/2006 - "We have tested adaphostin against both Philadelphia chromosome (Ph)-positive (K562, KBM5, KBM5-R [IM resistant KBM5], KBM7, and KBM7-R [IM-resistant KBM7]) and Ph-negative (OCI/AML2 and OCI/AML3) cells, and against cells from patients with chronic myeloid leukemia (CML) and acute myeloid leukemia (AML). "
01/01/2006 - "Interactions between the tyrphostin adaphostin and proteasome inhibitors (eg, MG-132 and bortezomib) were examined in multiple human leukemia cell lines and primary acute myeloid leukemia (AML) specimens. "

03/01/2007 - "These results suggest a primary role for ROS in adaphostin-induced apoptosis in glioblastoma. "
03/01/2007 - "Of the three glioblastoma cell lines, the U87 cells were least sensitive to adaphostin. "
03/01/2007 - "To delineate a role for reactive oxygen species (ROS) induction in adaphostin-induced apoptosis in glioblastoma cells. "
03/01/2007 - "Adaphostin cytoxicity in glioblastoma cells is ROS-dependent and is accompanied by upregulation of heme oxygenase-1."
12/01/2002 - "In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines."